NDAORALTABLETPriority Review
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
5/8 — Partial
Priority Review
QINLOCK (ripretinib) by Cipher Pharmaceuticals is stem cell factor (kit) receptor inhibitors [moa]. First approved in 2020.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QINLOCK (ripretinib) is an oral small-molecule kinase inhibitor targeting the stem cell factor (KIT) receptor, used to treat gastrointestinal stromal tumors (GIST). It works by inhibiting KIT signaling pathways that drive tumor growth in patients with advanced or metastatic disease.
$0.052BPart D
Peak16.0 years to LOEProduct is at peak maturity with modest Part D spending ($52M in 2023) and limited prescriber base (1,279 claims), suggesting a specialized oncology team focused on deep market penetration rather than broad expansion.
Mechanism of Action
Stem Cell Factor (KIT) Receptor Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
Ripretinib (QINLOCK®) According to Current SmPC
Started Oct 2024
10 enrolled
GIST - Gastrointestinal Stromal Tumor
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
Started Dec 2023
54 enrolled
GIST
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Started Nov 2021
0Gastrointestinal Stromal Tumors
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Started Sep 2021
13 enrolled
GIST - Gastrointestinal Stromal Tumor
Ripretinib in Chinese Patients With Advanced GIST: a Real World Study
Started May 2021
308 enrolled
Gastrointestinal Stromal Tumors
Worked on QINLOCK at Cipher Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.